Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
NCT05007093
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
DTC - Differentiated Thyroid Cancer
Interventions
DRUG:
Anlotinib hydrochloride
Sponsor
Yansong Lin